AIDS Alert Archives – August 1, 2010
August 1, 2010
View Archives Issues
-
Special Report: Youth & HIV Risk: Minority MSM population key part of growing epidemic in teens
HIV clinicians are seeing growing numbers of teenagers and adults under age 25 among new HIV infection cases. It's a phenomenon that has researchers and public health officials scrambling to develop biomedical HIV prevention interventions specifically for youth. -
Researchers must reach out to youth in trials
Investigators of HIV among teenagers and young adults need to develop additional and sometimes complex strategies for enrolling trial participants. -
Abstinence study finds risk reduction
As HIV researchers, clinicians, and public health officials continue to wait for an evidence-based biomedical prevention intervention, there remains a need for proven HIV prevention interventions targeting adolescents and young adults. -
HIV surveillance data lack demographics
Researchers studied the nature of the HIV epidemic in Maryland to show in one microcosm of the U.S. epidemic that different populations of at-risk individuals have different sub-types of the virus and will need to be handled differently. -
Obama warns of 'declining sense of urgency' on HIV
Editor's note: As this issue of AIDS Alert was going to press, the White House released its National HIV/AIDS Strategy. The is summarized as follows. Look to future issues of AIDS Alert for analysis and updates on plan. -
Abstract & Commentary: Searching for the genie in the genome
Health care providers have been constantly amazed at the variation in response to infection with HIV-1. In our clinic, we now routinely see elderly patients who have been on various antiretroviral regimens over the years but still persist with high CD4 counts and low viral loads. They are truly long-term non-progressors. -
FDA Notifications
On April 6, 2010, the FDA granted approval to a generic formulation of zidovudine injection USP, 10 mg/mL, packaged in 200 mg/20 mL single-use vials, manufactured by Pharmaforce, Inc., of Columbus, OH. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Retrovir® IV Infusion, 10 mg/mL, of VIIV Healthcare Co.